Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 6/2020

22.09.2020 | Research Article

Opportunistic screening of cardiovascular disease risk factors in community pharmacies in Nigeria: a cross-sectional study

verfasst von: Casmir Amadi, Folasade Lawal, Wale Ajiboye, Rosarii Agbim, Amam Mbakwem, Jayne Ajuluchukwu, David A. Oke

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Background Early identification and treatment of cardiovascular disease (CVD) risk factors through screening are crucial in the primary prevention of CVD and reduction in healthcare-related costs. Use of Non-Physician Healthcare-workers including Community Pharmacists has been advocated as an effective and cost-efficient model of healthcare delivery. In Nigeria the use of community pharmacists for mass screening of CVD risk factors has not been explored. Objective We sought to investigate the possibility of mass CVD risk factor screening in community pharmacies by pharmacists. Setting Lagos, Nigeria. Methods Between October and December 2018 eight hundred and eighty-nine apparently healthy participants were screened for obesity, hypertension, diabetes and hypercholesterolaemia in ten community pharmacies. Diabetes and hypercholesterolaemia were screened for using point-of-care testing modalities. A structured questionnaire was used to obtain the socio-demographic data of the participants. Main outcome measures Prevalence of overweight/obesity, hypertension, diabetes, hypercholesterolaemia, smoking and alcohol intake. Results Mean age of the subjects was 56.8 ± 21.1 years. Majority (57.4%) were females. Prevalence of smoking and alcohol intake were 4.3% and 26.7% respectively. 59.7% and 71.5% of males and females were either overweight (BMI ≥ 25 kg/m2) or obese (BMI ≥ 30 kg/m2) respectively. Prevalence of hypertension was 28.2% in all subjects, 30.9% in males and 26.3% in females, p < 0.001. Using BP > 130/80 mmHg prevalence of hypertension was 55.1%. Diabetes was detected in 3% of the subjects while 45.3% had hypercholesterolaemia. In total, 64.1% of the subjects were diagnosed with CVD risk factors for the first time. Conclusion Opportunistic screening for CVD risk factors is possible in community pharmacies and has the ability to detect previously undiagnosed risk factors. This community pharmacy based model could serve as a cost-effective approach to primary prevention of CVD.
Literatur
1.
Zurück zum Zitat World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. Geneva: World Health Organization; 2007. World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. Geneva: World Health Organization; 2007.
2.
Zurück zum Zitat Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747–57. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747–57.
3.
Zurück zum Zitat Bygbjerg IC. Double burden of non-communicable and infectious diseases in developing countries. Science. 2012;337(6101):1499–501. Bygbjerg IC. Double burden of non-communicable and infectious diseases in developing countries. Science. 2012;337(6101):1499–501.
4.
Zurück zum Zitat O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112–23. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112–23.
5.
Zurück zum Zitat Yusuf S, Hawken S, Ounpuu S, Dans T, Avzum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52. Yusuf S, Hawken S, Ounpuu S, Dans T, Avzum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.
6.
Zurück zum Zitat Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–53. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–53.
7.
Zurück zum Zitat Ferdinand KC, Patterson KP, Taylor C, Fergus IV, Nasser SA. Community-based approaches to prevention and management of hypertension and cardiovascular disease. J Clin Hypertens (Greenwich). 2012;14:336–43. Ferdinand KC, Patterson KP, Taylor C, Fergus IV, Nasser SA. Community-based approaches to prevention and management of hypertension and cardiovascular disease. J Clin Hypertens (Greenwich). 2012;14:336–43.
8.
Zurück zum Zitat O’Loughlin J, Masson P, Dery V, Fagnan D. The role of community pharmacists in health education and disease prevention: a survey of their interests and needs in relation to cardiovascular disease. Prev Med. 1999;28:324–31. O’Loughlin J, Masson P, Dery V, Fagnan D. The role of community pharmacists in health education and disease prevention: a survey of their interests and needs in relation to cardiovascular disease. Prev Med. 1999;28:324–31.
10.
Zurück zum Zitat Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother. 2007;41(11):1770–81. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother. 2007;41(11):1770–81.
11.
Zurück zum Zitat Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health. 2003;25(2):144–53. Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health. 2003;25(2):144–53.
12.
Zurück zum Zitat Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention program to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm. 2011;33(1):132–40. Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention program to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm. 2011;33(1):132–40.
13.
Zurück zum Zitat George J, McNamara GJ, Stewart K. The roles of community pharmacists in cardiovascular disease prevention and management. AMJ. 2011;4(5):266–72. George J, McNamara GJ, Stewart K. The roles of community pharmacists in cardiovascular disease prevention and management. AMJ. 2011;4(5):266–72.
14.
Zurück zum Zitat Santschi VS, Colosimo AL, Chilero A, Burnand B, Paradis G. Pharmacists interventions to improve cardiovascular risk factors in diabetes. A systematic review and meta-analysis. Diabetes Care. 2012;35:2706–17. Santschi VS, Colosimo AL, Chilero A, Burnand B, Paradis G. Pharmacists interventions to improve cardiovascular risk factors in diabetes. A systematic review and meta-analysis. Diabetes Care. 2012;35:2706–17.
15.
Zurück zum Zitat Horgan JPM, Blenkinsopp A, McManus RJ. Evaluation of a cardiovascular disease opportunistic risk assessment pilot (Heart MOT Service) in community pharmacies. J Pub Health. 2010;32(1):110–6. Horgan JPM, Blenkinsopp A, McManus RJ. Evaluation of a cardiovascular disease opportunistic risk assessment pilot (Heart MOT Service) in community pharmacies. J Pub Health. 2010;32(1):110–6.
16.
Zurück zum Zitat Jahangard-Rafsanjani Z, Hakimzadeh N, Sarayani A, et al. A community pharmacy-based cardiovascular risk screening service implemented in Iran. Pharm Pract (Granada). 2017;15(2):919. Jahangard-Rafsanjani Z, Hakimzadeh N, Sarayani A, et al. A community pharmacy-based cardiovascular risk screening service implemented in Iran. Pharm Pract (Granada). 2017;15(2):919.
18.
Zurück zum Zitat Osuji CU, Onwubuya EI, Ahaneku GI, Omejua EG. Pattern of cardiovascular admissions at the Nnamdi Azikiwe University Teaching Hospital, Nnewi South East Nigeria. Pan Afr Med J. 2014;17:116. Osuji CU, Onwubuya EI, Ahaneku GI, Omejua EG. Pattern of cardiovascular admissions at the Nnamdi Azikiwe University Teaching Hospital, Nnewi South East Nigeria. Pan Afr Med J. 2014;17:116.
19.
Zurück zum Zitat Oguanobi NI, Ejim EC, Onwubere BJ, Ike SO, Anisiuba BC, Ikeh VO, Aneke EO. Pattern of cardiovascular disease amongst medical admissions in a regional teaching hospital in South-eastern Nigeria. Nig J Cardiol. 2013;10:77–80. Oguanobi NI, Ejim EC, Onwubere BJ, Ike SO, Anisiuba BC, Ikeh VO, Aneke EO. Pattern of cardiovascular disease amongst medical admissions in a regional teaching hospital in South-eastern Nigeria. Nig J Cardiol. 2013;10:77–80.
20.
Zurück zum Zitat Hadiza S. Cardiovascular disease admissions in medical wards of a tertiary hospital in north-west Nigeria. IOSR J Dent Med Sci. 2018;17(5):47–50. Hadiza S. Cardiovascular disease admissions in medical wards of a tertiary hospital in north-west Nigeria. IOSR J Dent Med Sci. 2018;17(5):47–50.
23.
Zurück zum Zitat Amadi CE, Lawal FO, Mbakwem AC, Ajuluchukwu JN, Oke DA. Knowledge of cardiovascular disease risk factors and practice of primary prevention of cardiovascular disease by Community Pharmacists in Nigeria: a cross-sectional study. Int J Clin Pharm. 2018;40(6):1587–95. Amadi CE, Lawal FO, Mbakwem AC, Ajuluchukwu JN, Oke DA. Knowledge of cardiovascular disease risk factors and practice of primary prevention of cardiovascular disease by Community Pharmacists in Nigeria: a cross-sectional study. Int J Clin Pharm. 2018;40(6):1587–95.
24.
Zurück zum Zitat Rolland-Cachera MF, Sempe M, Guilloud-Bataille M, Patois E, et al. Adiposity Indices in children. Am J Clin Nutr. 1982;36:178–84. Rolland-Cachera MF, Sempe M, Guilloud-Bataille M, Patois E, et al. Adiposity Indices in children. Am J Clin Nutr. 1982;36:178–84.
25.
Zurück zum Zitat National Cholesterol Education Program (NCEP): Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002 106; 3143–3421. National Cholesterol Education Program (NCEP): Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002 106; 3143–3421.
26.
Zurück zum Zitat Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2018;138:e484–594. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2018;138:e484–594.
28.
Zurück zum Zitat Reiner Z, Catapano AL, De Backer G, Graham I, Tasknen MR, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–818. Reiner Z, Catapano AL, De Backer G, Graham I, Tasknen MR, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–818.
30.
Zurück zum Zitat Bovet P, Hirsiger P, Emery F, De Bernardini J, Rossier C, Trebeljahr J, Hagon-Traub I. Impact and cost of a 2-week community-based screening and awareness program for diabetes and cardiovascular risk factors in a Swiss canton. Diabetes Metab Syndr Obes. 2011;4:213–23. https://doi.org/10.2147/DMSO.S20649.CrossRef Bovet P, Hirsiger P, Emery F, De Bernardini J, Rossier C, Trebeljahr J, Hagon-Traub I. Impact and cost of a 2-week community-based screening and awareness program for diabetes and cardiovascular risk factors in a Swiss canton. Diabetes Metab Syndr Obes. 2011;4:213–23. https://​doi.​org/​10.​2147/​DMSO.​S20649.CrossRef
31.
Zurück zum Zitat Carter M, Karwalajtys T, Chambers L, Kaczorowski J, Dolovich L, Gierman T, et al. Implementing a standardized community-based cardiovascular risk assessment program in 20 Ontario communities. Health Promot Int. 2009;24(4):325–33. Carter M, Karwalajtys T, Chambers L, Kaczorowski J, Dolovich L, Gierman T, et al. Implementing a standardized community-based cardiovascular risk assessment program in 20 Ontario communities. Health Promot Int. 2009;24(4):325–33.
32.
Zurück zum Zitat Chiazor EI, Evans M, van Worden H, Oparah AC. A systematic review of community pharmacists’ interventions in reducing major risk factors for cardiovascular disease. J Value Health Reg Issue. 2015;7c:9–21. Chiazor EI, Evans M, van Worden H, Oparah AC. A systematic review of community pharmacists’ interventions in reducing major risk factors for cardiovascular disease. J Value Health Reg Issue. 2015;7c:9–21.
33.
Zurück zum Zitat George J, McNamara K, Stewart K. The roles of community pharmacists in cardiovascular disease prevention and management. Aust Med J. 2011;4(5):266–72. George J, McNamara K, Stewart K. The roles of community pharmacists in cardiovascular disease prevention and management. Aust Med J. 2011;4(5):266–72.
34.
Zurück zum Zitat Mangum SA, Kraenow KR, Narducci WA. Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects. J Am Pharm Assoc (Wash). 2003;43(1):50–5. Mangum SA, Kraenow KR, Narducci WA. Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects. J Am Pharm Assoc (Wash). 2003;43(1):50–5.
35.
Zurück zum Zitat Onyemelukwe GC, Ogunfowokan O, Mbakwem A, Alao AK, Soroh K, Omorodion O, Abreu P. Cardiovascular risk factors in adult general out-patient clinics in Nigeria: a country analysis of the Africa and Middle East Cardiovascular Epidemiological (ACE) study. Afr Health Sci. 2017;17(4):1070–81. Onyemelukwe GC, Ogunfowokan O, Mbakwem A, Alao AK, Soroh K, Omorodion O, Abreu P. Cardiovascular risk factors in adult general out-patient clinics in Nigeria: a country analysis of the Africa and Middle East Cardiovascular Epidemiological (ACE) study. Afr Health Sci. 2017;17(4):1070–81.
37.
Zurück zum Zitat Adeloye D, Basquill C, Aderemi AV, et al. An estimate of the prevalence of hypertension in Nigeria: a systematic review and meta-analysis. J Hypertens. 2015;33(2):230–42. Adeloye D, Basquill C, Aderemi AV, et al. An estimate of the prevalence of hypertension in Nigeria: a systematic review and meta-analysis. J Hypertens. 2015;33(2):230–42.
38.
Zurück zum Zitat Vincent-Onabajo GO, Adaji JO, Umeonwuka CI. Prevalence of undiagnosed hypertension among traders at a regional market in Nigeria. Ann Med Health Sci Res. 2017;7:97–101. Vincent-Onabajo GO, Adaji JO, Umeonwuka CI. Prevalence of undiagnosed hypertension among traders at a regional market in Nigeria. Ann Med Health Sci Res. 2017;7:97–101.
40.
Zurück zum Zitat Ogbera OA, Ekpebegh C. Diabetes mellitus in Nigeria: the past, present and future. World J Diabetes. 2014;5(6):905–11. Ogbera OA, Ekpebegh C. Diabetes mellitus in Nigeria: the past, present and future. World J Diabetes. 2014;5(6):905–11.
41.
Zurück zum Zitat Uloko AE, Musa BM, Ramalan MA, Gezewa ID, Puepet FH, Uloko AT, et al. Prevalence and risk factors for diabetes mellitus in Nigeria: a systematic review and meta-analysis. Diabetes Ther. 2018;9(3):1307–16. Uloko AE, Musa BM, Ramalan MA, Gezewa ID, Puepet FH, Uloko AT, et al. Prevalence and risk factors for diabetes mellitus in Nigeria: a systematic review and meta-analysis. Diabetes Ther. 2018;9(3):1307–16.
42.
Zurück zum Zitat Akarolo-Anthony SN, Willett WC, Spigelman D, Adebamowo CA. Obesity epidemic has emerged among Nigerians. BMC Pub Health. 2014;14:455. Akarolo-Anthony SN, Willett WC, Spigelman D, Adebamowo CA. Obesity epidemic has emerged among Nigerians. BMC Pub Health. 2014;14:455.
45.
Zurück zum Zitat Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, et al. Metabolic syndrome in the PAMELA study: daily life blood pressure, cardiac damage, and prognosis. Hypertension. 2007;49:40–7. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, et al. Metabolic syndrome in the PAMELA study: daily life blood pressure, cardiac damage, and prognosis. Hypertension. 2007;49:40–7.
46.
Zurück zum Zitat Cohen HW, Hailpern SM, Alderman MH. Glucose–cholesterol interaction magnifies coronary heart disease for hypertensive patients. Hypertension. 2004;43:983–7. Cohen HW, Hailpern SM, Alderman MH. Glucose–cholesterol interaction magnifies coronary heart disease for hypertensive patients. Hypertension. 2004;43:983–7.
47.
Zurück zum Zitat Mancia G, Parati G, Borghi C, Ghironzi G, et al. Smooth investigators. Hypertension prevalence, awareness, control and association with metabolic abnormalities in San Maniano population the SMOOTH Study. J Hypertens. 2006;24:837–43. Mancia G, Parati G, Borghi C, Ghironzi G, et al. Smooth investigators. Hypertension prevalence, awareness, control and association with metabolic abnormalities in San Maniano population the SMOOTH Study. J Hypertens. 2006;24:837–43.
48.
Zurück zum Zitat Jahangard-Rafsanjani Z, Sarayani A, Javadi M, Hadjibabaie M, Rashidian A, Ahmadvand A, Gholami K. Pharmacists’ attitudes and perceived barriers about community pharmacy-based cardiovascular risk screening services. J Pharm Care. 2014;2(4):142–8. Jahangard-Rafsanjani Z, Sarayani A, Javadi M, Hadjibabaie M, Rashidian A, Ahmadvand A, Gholami K. Pharmacists’ attitudes and perceived barriers about community pharmacy-based cardiovascular risk screening services. J Pharm Care. 2014;2(4):142–8.
49.
Zurück zum Zitat Azami Aghdash S, Ghojazadeh M, Shams-Vahdati S, Piri R, Klvany Kh, Yaghoubi R, Asli Z, Naghavi-Behzad M. Barriers and strategies for identifying and managing risk factors of cardiovascular diseases in levels of preventing, screening, and treating. J Anal Res Clin Med. 2015;3(4):197–205. Azami Aghdash S, Ghojazadeh M, Shams-Vahdati S, Piri R, Klvany Kh, Yaghoubi R, Asli Z, Naghavi-Behzad M. Barriers and strategies for identifying and managing risk factors of cardiovascular diseases in levels of preventing, screening, and treating. J Anal Res Clin Med. 2015;3(4):197–205.
50.
Zurück zum Zitat Holland RW, Nimmo CM. Transitions in pharmacy practice, part 3: effecting change–the three-ring circus. Am J Health Syst Pharm. 1999;56:2235–41. Holland RW, Nimmo CM. Transitions in pharmacy practice, part 3: effecting change–the three-ring circus. Am J Health Syst Pharm. 1999;56:2235–41.
51.
Zurück zum Zitat Anderson C. Health Promotion in community pharmacy: the UK situation. Patient Educ Couns. 2000;39:285–91. Anderson C. Health Promotion in community pharmacy: the UK situation. Patient Educ Couns. 2000;39:285–91.
52.
Zurück zum Zitat Hindi AMK, Schafheutle EI, Jacobs S. Patient and public perspectives of community pharmacies in the United Kingdom: a systematic review. Health Expect. 2018;21:409–28. Hindi AMK, Schafheutle EI, Jacobs S. Patient and public perspectives of community pharmacies in the United Kingdom: a systematic review. Health Expect. 2018;21:409–28.
53.
Zurück zum Zitat Taylor J, Krska J, Mackridge A. A community pharmacy-based cardiovascular screening service: views of service users and the public. Int J Pharm Pract. 2012;20:277–84. Taylor J, Krska J, Mackridge A. A community pharmacy-based cardiovascular screening service: views of service users and the public. Int J Pharm Pract. 2012;20:277–84.
54.
Zurück zum Zitat Ogunbayo OJ, Schafheutle EI, Cutts C, Noyce PR. Self-care of long-term conditions: patients’ perspectives and their (limited) use of community pharmacies. Int J Clin Pharm. 2017;39:433–42. Ogunbayo OJ, Schafheutle EI, Cutts C, Noyce PR. Self-care of long-term conditions: patients’ perspectives and their (limited) use of community pharmacies. Int J Clin Pharm. 2017;39:433–42.
55.
Zurück zum Zitat Fakih S, Marriott JL, Boardman H, Anderson C, Hussainy SY. Comparing women pharmacy consumers’ experiences with weight loss treatment in Victoria and Nottingham: a cross-sectional study. BMC Public Health. 2014;14:662. Fakih S, Marriott JL, Boardman H, Anderson C, Hussainy SY. Comparing women pharmacy consumers’ experiences with weight loss treatment in Victoria and Nottingham: a cross-sectional study. BMC Public Health. 2014;14:662.
Metadaten
Titel
Opportunistic screening of cardiovascular disease risk factors in community pharmacies in Nigeria: a cross-sectional study
verfasst von
Casmir Amadi
Folasade Lawal
Wale Ajiboye
Rosarii Agbim
Amam Mbakwem
Jayne Ajuluchukwu
David A. Oke
Publikationsdatum
22.09.2020
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 6/2020
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01112-2

Weitere Artikel der Ausgabe 6/2020

International Journal of Clinical Pharmacy 6/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.